IBD

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Boeing, Brooge, Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, March 1, 2024
Boeing, News, Fraud, Neurobiology of Aging, Apoptosis, Cassava Sciences, MAX, City University, P.C, ALS, Initiative, Cassava, AMX0035, Journal, IBD, Security (finance), Evercore, Amyotrophy, Alaska Airlines, BROG, BIA, Complaint, Safety, Biomarker, Crash, Amylyx Pharmaceuticals, Science, Prescription, Scientific misconduct, BBC World Service, Alzheimer's disease, FDA, Food, Data management, Investor's Business Daily, Gaping, Risk, Patient, Cognition, Defendant, Pharmaceutical industry

Its Commercial Airplanes Segment is a leading producer of commercial aircraft and offers a family of commercial jetliners including its 737 MAX.

Key Points: 
  • Its Commercial Airplanes Segment is a leading producer of commercial aircraft and offers a family of commercial jetliners including its 737 MAX.
  • Throughout the Class Period, Defendants continued to assure investors that Boeing was laser-focused on safety and quality.
  • These false and misleading statements caused Boeing stock to trade at artificially inflated prices during the Class Period.
  • Also, according to the filed complaint, it took a near disaster to expose this heightened safety risk.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amylyx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – AMLX

Retrieved on: 
Wednesday, February 28, 2024
Pomerantz, Court, ALS, Person, Prior, Food, Complaint, District court, Apoptosis, Ext, AMX0035, Patient, LLP, IBD, Evercore, Action Replay, Amyotrophy, Prescription, Pharmaceutical industry

NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.

Key Points: 
  • NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc.  (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Boeing, Brooge, Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, February 26, 2024
Boeing, News, Fraud, Neurobiology of Aging, Apoptosis, Cassava Sciences, MAX, City University, P.C, ALS, Initiative, Cassava, AMX0035, Journal, IBD, Security (finance), Evercore, Amyotrophy, Alaska Airlines, BROG, BIA, Complaint, Safety, Biomarker, Crash, Amylyx Pharmaceuticals, Science, Prescription, Scientific misconduct, BBC World Service, Alzheimer's disease, FDA, Food, Data management, Investor's Business Daily, Gaping, Risk, Patient, Cognition, Defendant, Pharmaceutical industry

Its Commercial Airplanes Segment is a leading producer of commercial aircraft and offers a family of commercial jetliners including its 737 MAX.

Key Points: 
  • Its Commercial Airplanes Segment is a leading producer of commercial aircraft and offers a family of commercial jetliners including its 737 MAX.
  • Throughout the Class Period, Defendants continued to assure investors that Boeing was laser-focused on safety and quality.
  • These false and misleading statements caused Boeing stock to trade at artificially inflated prices during the Class Period.
  • Also, according to the filed complaint, it took a near disaster to expose this heightened safety risk.

AMYLYX SHAREHOLDER NOTICE: Faruqi & Faruqi Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Amylyx To Contact Him Directly To Discuss Their Options

Retrieved on: 
Friday, February 23, 2024
Court, BBC World Service, Advertising, Investor's Business Daily, Woman, Patient, Amylyx Pharmaceuticals, LLP, IBD, Evercore, Prescription, Pharmaceutical industry

NEW YORK, Feb. 23, 2024 (GLOBE NEWSWIRE) --  Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ: AMLX) and reminds investors of the April 9, 2024 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Key Points: 
  • If you suffered losses exceeding $100,000 investing in Amylyx stock or options between November 11, 2022 and November 8, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext.
  • Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Amylyx’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Morphic Announces Corporate Highlights and Financial Results for the Full Year 2023

Retrieved on: 
Thursday, February 22, 2024
Ulcerative colitis, BID, Research, Biotechnology, Friends, ATM, Cardiac output, AbbVie, Conditional sentence, DDW, Inflammatory bowel disease, Patient, TL1A, Clinical trial, Janssen, IBD, PIPE, Insurance, Pharmaceutical industry

WALTHAM, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the full year 2023.

Key Points: 
  • -Ended 2023 with $704.3 million in cash and equivalents; cash runway into second half of 2027-
    WALTHAM, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today reported corporate highlights and financial results for the full year 2023.
  • “Today, our conviction in MORF-057 as a potential oral, well tolerated, and efficacious treatment for inflammatory bowel disease (IBD) is stronger than ever, based on the clear success of the EMERALD-1 trial in UC.
  • Looking forward in 2024, we will work to translate this momentum into further progress with the GARNET phase 2 study in patients with moderately to severely active Crohn’s disease running in parallel with the EMERALD-2 phase 2b study in UC,” commented Praveen Tipirneni, Chief Executive Officer of Morphic.
  • We believe that our cash, cash equivalents and marketable securities of $704.3 million as of December 31, 2023, will enable us to fund our operating expenses and capital expenditure requirements into the second half of 2027

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, February 22, 2024
Scientific misconduct, City University, ALS, BBC World Service, Alzheimer's disease, Cassava Sciences, FDA, News, Food, Data management, Investor's Business Daily, Neurobiology of Aging, Complaint, Apoptosis, Safety, Initiative, Cassava, AMX0035, Biomarker, Patient, Cognition, Journal, Amylyx Pharmaceuticals, IBD, Evercore, Science, Defendant, Amyotrophy, Prescription, P.C, Pharmaceutical industry

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Amylyx class action go to: https://bespc.com/cases/AMLX

Kirby McInerney LLP Reminds Amylyx Pharmaceuticals, Inc. (AMLX) Investors of Class Action Filing and Encourages Investors to Contact the Firm

Retrieved on: 
Wednesday, February 21, 2024
Court, ALS, District court, AMX0035, Patient, IBD, Evercore, Amyotrophy, Pharmaceutical industry

Investors have until April 4, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until April 4, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Amylyx is a commercial-stage biotechnology company that engages in the discovery and development of treatments for Amyotrophic Lateral Sclerosis (“ALS”) and other neurodegenerative diseases.
  • The Company’s products include, among others, AMX0035 (commercially referred to as “RELYVRIO” in the U.S.), for the treatment of ALS.
  • Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Amylyx Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – AMLX

Retrieved on: 
Tuesday, February 20, 2024
Pomerantz, Court, ALS, Person, Prior, Food, Complaint, District court, Apoptosis, Ext, AMX0035, Patient, LLP, IBD, Evercore, Action Replay, Amyotrophy, Prescription, Pharmaceutical industry

NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.

Key Points: 
  • NEW YORK, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Amylyx Pharmaceuticals, Inc. (“Amylyx” or the “Company”) (NASDAQ: AMLX) and certain officers.
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on: 
Sunday, February 18, 2024
Scientific misconduct, City University, ALS, BBC World Service, Alzheimer's disease, Cassava Sciences, FDA, News, Food, Data management, Investor's Business Daily, Neurobiology of Aging, Complaint, Apoptosis, Safety, Initiative, Cassava, AMX0035, Biomarker, Patient, Cognition, Journal, Amylyx Pharmaceuticals, IBD, Evercore, Science, Defendant, Amyotrophy, Prescription, P.C, Pharmaceutical industry

Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.

Key Points: 
  • Stockholders have until the deadlines below to petition the court to serve as lead plaintiff.
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Amylyx class action go to: https://bespc.com/cases/AMLX

Kirby McInerney LLP Reminds Amylyx Pharmaceuticals, Inc. (AMLX) Investors of Class Action Filing and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, March 1, 2024
Class Action Lawsuit, Professional Services, Legal, Court, ALS, District court, AMX0035, Patient, IBD, Evercore, Amyotrophy, Pharmaceutical industry

Investors have until April 4, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until April 4, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Amylyx is a commercial-stage biotechnology company that engages in the discovery and development of treatments for Amyotrophic Lateral Sclerosis (“ALS”) and other neurodegenerative diseases.
  • The Company’s products include, among others, AMX0035 (commercially referred to as “RELYVRIO” in the U.S.), for the treatment of ALS.
  • Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation.